

Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage

Questa è la versione Post print del seguente articolo:

*Original*

Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage / Scarpa, Fabio; Imperia, Elena; Azzena, Ilenia; Giovanetti, Marta; Benvenuto, Domenico; Locci, Chiara; Casu, Marco; Fiori, Pier Luigi; Maruotti, Antonello; Ceccarelli, Giancarlo; Borsetti, Alessandra; Caruso, Arnaldo; Cauda, Roberto; Cassone, Antonio; Via, Allegra; Pascarella, Stefano; Sanna, Daria; Ciccozzi, Massimo. - In: JOURNAL OF INFECTION. - ISSN 0163-4453. - (2023). [10.1016/j.jinf.2023.02.039]

*Availability:*

This version is available at: 11388/304047 since: 2024-03-03T10:43:13Z

*Publisher:*

*Published*

DOI:10.1016/j.jinf.2023.02.039

*Terms of use:*

Chiunque può accedere liberamente al full text dei lavori resi disponibili come "Open Access".

*Publisher copyright*

note finali coverpage

(Article begins on next page)



Contents lists available at ScienceDirect

Journal of Infection

journal homepage: [www.elsevier.com/locate/jinf](http://www.elsevier.com/locate/jinf)

## Letter to the Editor

### Genetic and structural genome-based survey reveals the low potential for epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage

Dear Editor,

We read with interest the Letter to the Editor *Evolution of SARS-CoV-2 Omicron subvariants BF.7 and XBB.1.5: Time to follow Africa and abort all COVID restrictions* by Kelleni,<sup>1</sup> on the need, for the global health care authorities, to carefully consider the African COVID-19 safe and effective early treatment approach. In such a context, here we report on the global epidemic trajectory of SARS-CoV-2 XBB.1.5 lineage that we believe the above Authorities should consider in taking their decisions.

The phylogenomic reconstruction, available at <https://gisaid.org/phyldynamics/global/nextstrain/>, depicts an evolutionary pattern of XBB.1.5 very similar to that of previous, recent variants such as BA.2.75,<sup>2</sup> BA.2.12.1 and BQ.1<sup>3</sup> that appeared as an evolutionary blind background. Notably, this pattern has also been identified for the original recombinant XBB and its first descendant XBB.1,<sup>4</sup> which are now known not to exhibit characteristics of epidemiologically dangerous lineages. Actually, the XBB.1.5 lineage represents the first descendant of the recombinant XBB for which threats on public health impact originally arose. As of now, it has been detected in 54 countries and its speed of diffusion prompted the WHO to revise the confidence level of the risk assessment from low (January 11, 2023) to moderate (January 25, 2022).<sup>5</sup> However, the Bayesian Skyline Plot (BSP) in Fig. 1 (estimated on all high-quality genomes and coverage available on January 13, 2023 from the GSAID portal (<https://gisaid.org/>) by following Scarpa et al.<sup>2,4,6</sup>), indicates quite a low level of genetic variability with very few fluctuation points over time. The viral genetic variability and the population size peaked reaching the plateau around November 24, 2022. This substantial lack of genetic variation during the time (also depicted by branches' length in the phylogenetic tree shown in Fig. S1) is not the trend of a lineage that is about to explode in terms of population size and, accordingly, in terms of contagiousness. Indeed, at the beginning of the pandemic, the genetic variability of SARS-CoV2 ancestral strain was shortly and quickly increasing with a very vertical curve.<sup>7</sup> Conversely, XBB.1.5 seems to be quite typical of an evolutionary lineage that presents new features in comparison to its direct progenitor and to other recent variants, but unable to promote an abnormal expansion. The estimated evolutionary rate for XBB.1.5 ( $6.9 \times 10^{-4}$  subs/site/year) further accounts for the low genetic variability and limited capacity for strong demographic expansion. The evolutionary rate of the variant BA.5, which remained dominant worldwide for several months in 2022, was slightly higher ( $7.4 \times 10^{-4}$  subs/site/year),<sup>2</sup> but

BA.5 had been circulating for several months before peaking, and its plateau phase presented several fluctuations of the viral population size.<sup>2</sup> A direct comparison of evolutionary rates of recent versus early SARS-CoV-2 strains should be taken cautiously because of the different population susceptibilities to infection among unvaccinated, vaccinated and preinfected subjects. Nonetheless, it remains noteworthy that the evolutionary rate of the pandemic starting, SARS-CoV-2 Wuhan-Hu-1 strain, was around  $6.58 \times 10^{-3}$  subs/site/year,<sup>8</sup> i.e., roughly 10 times faster than XBB.1.5.

The lineage XBB.1.5 presents the same point mutations of interest in the spike protein sequence as its progenitor XBB (i.e., K417N, S477N, N501Y and P681H),<sup>4</sup> except for mutation at position 486.<sup>9</sup> Indeed, the NTD domain is identical for XBB.1 and XBB.1.5 whereas their RBDs only differ for the mutations at position 486, where the original Wuhan Phe (conserved in BA.2) is replaced by a Ser in XBB and XBB.1,<sup>4</sup> and a Pro in XBB.1.5. The predicted net electrostatic charges of the RBD and NTD domains, the changes of which have been reported to impact on virus transmissibility and infectivity, are reported in Table 1. While the three XBB descendants differ from BA.2 for their negative net charge on NTD, being in this similar to the first Omicron variant, the BA.1,<sup>10</sup> no evident differences between lineages XBB/XBB.1 and XBB.1.5 are present in the distribution of the electrostatic surface potential of NTD and RBD. The conserved F486 in BA.2 can establish Van der Waals contacts with residues in a hydrophobic pocket on the ACE2 receptor. The substituting Ser in XBB and XBB.1 tends to destabilize the RBD-ACE2 interface by disrupting hydrophobic interactions. Consistently, the interaction BA.2 RBD-ACE2 is inferred to be the most stable among the four tested variants.


It should also be pointed out that XBB.1.5, as all these recent, BA.2 and BA.5-derived Omicron subvariants, have remained so far confined to selected regional areas of the USA, despite its high transmissibility and immune-evasion potential, as reported by "COVID data tracker" of the Centers for Disease Control and Prevention (CDC).<sup>3</sup> Thus, the data reported here and our interpretation of a limited expansion potential of XBB.1.5 appear to be well in keeping with the current epidemiological, real-world observations.

In conclusion, genetic and structural analyses here presented do not provide evidence for a particularly high risk of XBB.1.5 expansion to become a new, global public health threat. The Omicron variant of concern, and more specifically BA.5 and its descendant lineages, remain the dominant variants circulating globally.<sup>5</sup> The variant XBB.1.5 appears to spread even more slowly than the last subvariants that have caused concerns in 2022. However, it cannot be excluded that new mutations will occur and make XBB.1.5 more dangerous. In this context, extensive genome-based monitoring must continue uninterrupted because it is the only way to identify and/or predict important changes in the genomic composition of SARS-CoV-2.

Daria Sanna and Massimo Ciccozzi contributed equally to this work.

<https://doi.org/10.1016/j.jinf.2023.02.039>

0163-4453/© 2023 The British Infection Association. Published by Elsevier Ltd. All rights reserved.



**Fig. 1.** Bayesian skyline plot of SARS-CoV-2 XBB.1.5 variant. The viral effective population size (y-axis) is shown as a function of days (x-axis). Solid area represents the 95% high posterior density (HPD) region. Demographic analysis has been performed by using BEAST 1.10.4 [27] following Scarpa et al.<sup>3</sup> Figure has been edited by using the software GIMP 2.8 (available at <https://www.gimp.org/downloads/oldstable/>).

**Table 1**

Net charge of NTD and RBD for BA.2, XBB, XBB.1, and XBB.1.5.

	BA.2	XBB	XBB.1	XBB.1.5
NTD	0.95 ± 0.04	1.14 ± 0.04	1.18 ± 0.04	1.18 ± 0.04
RBD	5.19 ± 0.01	5.45 ± 0.02	5.45 ± 0.02	5.42 ± 0.01

## Funding

This research was funded by FONDAZIONE DI SARDEGNA bando 2022–2023 for the Dipartimento di Scienze Biomediche - UNISS (to Fabio Scarpa and Daria Sanna). Marta Giovanetti is funded by PON “Ricerca e Innovazione” 2014–2020 and by the CRP–ICGEB RESEARCH GRANT 2020 Project CRP/BRA20-03, contract CRP/20/03, Oswaldo Cruz Foundation. Stefano Pascarella is in part supported by the Sapienza grant n. RP12117A7670A1E8.

## Author contributions

FS and MC (Massimo Ciccozzi) developed the study design. FS, AV, and SP analyzed data. FS and MC (Massimo Ciccozzi) wrote the original draft manuscript. All of the authors revised the manuscript. All authors read and approved the manuscript.

## Conflicts of interest

The authors declare no conflict of interest.

## Acknowledgments

We would like to thank all the authors who have kindly deposited and shared genomes on GSAID.

## Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.jinf.2023.02.039](https://doi.org/10.1016/j.jinf.2023.02.039).

## References

- Kelleni MT. Evolution of SARS-CoV-2 Omicron subvariants BF.7 and XBB.1.5: time to follow Africa and abort all COVID restrictions. *J Infect* 2023. <https://doi.org/10.1016/j.jinf.2023.01.027>. (in press).
- Scarpa F, Sanna D, Azzena I, Giovanetti M, Benvenuto D, Angeletti S, et al. On the SARS-CoV-2 BA.2.75 variant: a genetic and structural point of view. *J Med Virol* 2022;**95**:e28119. <https://doi.org/10.1002/jmv.28119>
- Centers for Disease Control and Prevention (CDC) - COVID data tracker. (<https://covid.cdc.gov/covid-data-tracker/#variant-proportions>), last accessed on February 6, 2023.
- Scarpa F, Sanna D, Azzena I, Casu M, Cossu P, Fiori PL, et al. Genome-based comparison between the recombinant SARS-CoV-2 XBB and its parental lineages. *J Med Virol* 2023. <https://doi.org/10.1002/jmv.28625>. (in press).
- World Health Organization. WHO XBB.1.5 Updated Rapid Risk Assessment, 25 January 2023. ([https://www.who.int/docs/default-source/coronaviruse/25012023xbb.1.pdf?sfvrsn=c3956081\\_1/Weekly](https://www.who.int/docs/default-source/coronaviruse/25012023xbb.1.pdf?sfvrsn=c3956081_1/Weekly)) epidemiological update on COVID-19 - 8 February 2023. <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-8-february-2023>, last accessed on February 13, 2023.
- Scarpa F, Sanna D, Benvenuto D, Borsetti A, Azzena I, Casu M, et al. Genetic and structural data on the SARS-CoV-2 Omicron BQ.1 variant reveal its low potential for epidemiological expansion. *Int J Mol Sci* 2022;**23**:15264. <https://doi.org/10.3390/ijms232315264>
- Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2. *J Med Virol* 2020;**92**:675–9. <https://doi.org/10.1002/jmv.25723>
- Benvenuto D, Giovanetti M, Salemi M, Proserpi M, De Flora C, Alcantara LCJ, et al. The global spread of 2019-nCoV: a molecular evolutionary analysis. *Pathog Glob Health* 2020;**114**(2):64–7. <https://doi.org/10.1080/20477724.2020.1725339>
- Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell* 2023;**186**(2):279–86. <https://doi.org/10.1016/j.cell.2022.12.018>
- Pascarella S, Ciccozzi M, Benvenuto D, Borsetti A, Cauda R, Cassone A. Peculiar variations of the electrostatic potential of spike protein N-terminal domain associated with the emergence of successive SARS-CoV-2 Omicron lineages. *J Infect* 2023;**86**(1):66–117. <https://doi.org/10.1016/j.jinf.2022.07.018>

Fabio Scarpa\*

Department of Biomedical Sciences, University of Sassari, Sassari, Italy

Elena Imperia

Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italy  
Unit of Gastroenterology, Department of Medicine, University Campus Bio-Medico of Rome, 00128 Rome, Italy

Ilenia Azzena

Department of Biomedical Sciences, University of Sassari, Sassari, Italy  
Department of Veterinary Medicine, University of Sassari, Sassari, Italy

Marta Giovanetti

Laboratório de Flavivírus, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Rio de Janeiro, Brazil  
Department of Science and Technology for Humans and the Environment, University of Campus Bio-Medico di Roma, Rome, Italy

Domenico Benvenuto

Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italy

Chiara Locci

Department of Biomedical Sciences, University of Sassari, Sassari, Italy  
Department of Veterinary Medicine, University of Sassari, Sassari, Italy

Marco Casu

Department of Veterinary Medicine, University of Sassari, Sassari, Italy

Pier Luigi Fiori

Department of Biomedical Sciences, University of Sassari, Sassari, Italy  
Azienda Ospedaliera Universitaria (AOU) Sassari, Sassari, Italy

Antonello Maruotti

Department GEPLI, Libera Università Ss Maria Assunta, 00193 Rome, Italy

Giancarlo Ceccarelli

Department of Public Health and Infectious Diseases, University

Hospital Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

Alessandra Borsetti

National HIV/AIDS Research Center, Istituto Superiore di Sanità, 00161 Rome, Italy

Arnaldo Caruso

Department of Molecular and Translational Medicine, Section of Microbiology, University of Brescia, 25123 Brescia, Italy

Roberto Cauda

UOC Malattie Infettive, Infectious Disease Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy

Antonio Cassone

Center of Genomic, Genetic and Biology, 53100 Siena, Italy

Allegra Via, Stefano Pascarella

Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza Università di Roma, 00185 Rome, Italy

Daria Sanna

Department of Biomedical Sciences, University of Sassari, Sassari, Italy

Massimo Ciccozzi

Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, Rome, Italy

\*Correspondence to: University of Sassari, Department of Biomedical Sciences, Sassari, Italy

E-mail address: [fscarpa@uniss.it](mailto:fscarpa@uniss.it) (F. Scarpa).